Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones

Molecules

Volumn 17, Issue 1, 2012, Pages 884-896

  Lou, Qinghua ^a   Meng, Xiangbao ^a   Lao, Zhiqi ^a   Xuan, Lingling ^b   Bai, Jinye ^b   Hou, Qi ^a   Hu, Gaoyun ^c   Luo, Renna ^d   Tao, Lijian ^d   Li, Zhongjun ^a  

^a PEKING UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antifibrotic; Carbohydrate modified; Fluorofenidone; Glucose; Pirfenidone

Indexed keywords

5 METHYL 1 (3 FLUOROPHENYL) 2 (1H) PYRIDONE; 5-METHYL-1-(3-FLUOROPHENYL)-2-(1H)-PYRIDONE; MONOSACCHARIDE; PIRFENIDONE; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CHEMICAL PHENOMENA; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; FIBROSIS; IC 50; MOUSE; SOLUBILITY; SYNTHESIS;

ANIMALS; CELL PROLIFERATION; DRUG DESIGN; FIBROSIS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITORY CONCENTRATION 50; MICE; MONOSACCHARIDES; NIH 3T3 CELLS; PYRIDONES; SOLUBILITY;

EID: 84862942536     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17010884     Document Type: Article

References (22)

1. du Bois, R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug Dis. 2010, 9, 129-140.
2. Balsano1, C.; Alisi, A.; Nobili, V. Liver fibrosis and therapeutic strategies: The goal for improving metabolism. Curr. Drug Targets 2009, 10, 505-512.
3. Krenning, G.; Zeisberg, E.M.; Kalluri, R. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell Physiol. 2010, 225, 631-637.
4. Weber, K.T. Fibrosis and hypertensive heart disease. Curr. Opin. Cardiol. 2000, 5, 264-272. (Pubitemid 30496722)
5. Wick, G.; Backovic, A.; Rabensteiner, E.; Plank, N.; Schwentner, C.; Sgonc, R. The immunology of fibrosis: Innate and adaptive responses. Trends Immunol. 2010, 31, 110-119.
6. Azuma, A. Pirfenidone: Antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev. Resp. Med. 2010, 4, 301-310.
7. Iyer, S.N.; Hyde, D.M.; Giri, S.N. Anti-inflammatory effect of pirfenidone in the bleomycinhamster model of lung inflammation. Inflammation 2000, 24, 477-491. (Pubitemid 30452555)
8. Spond, J.; Case, N.; Chapman, R.W.; Crawley, Y.; Egan, R.W.; Fine, J.; Hey, J.A.; Kreutner, W.; Kung, T.; Wang, P.; Minnicozzi, M. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm. Pham. Ther. 2003, 16, 207-214. (Pubitemid 36798118)
9. Tao, L.; Hu, G. 1-(substituted phenyl)-5-methyl-2-(1H) pyridone in the manufacture of medicaments for treating fibrosis in organs or tissues. PCT Int. Appl. WO 2006/108354 A1, 19 October 2000.
10. Hu, G.; Tao, L.; Chen, J. Preparation methods and uses of 1-(substituted aryl)-5-trifluoromethyl- 2-(1H) pyridone compounds and their salts. PCT Int. Appl. WO2010/135972 A1, 2 December 2010.
11. Tao, L.; Zhang, J.; Hu, G.; Chen, Z.; Gong, J. Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H)- pyridone on renal fibroblast in rats. J. Cent. South Univ. (Med. Sci.) 2004, 29, 139-141.
12. Peng, Z.; Hu, G.; Shen, H.; Wang, L.; Ning, W.; Xie, Y.; Wang, N.; Li, B.; Tang, Y.; Tao, L. Fluorofenidone attenuates collagen I and transforming growth factor-1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology 2009, 14, 565-572.
13. Shimizu, T.; Fukagawa, M.; Kuroda, T.; Hata, S.; Iwasaki, Y.; Nemoto, M.; Shirai, K.; Yamauchi, S.; Margolin, S.B.; Shimizu, F.; Kurokawa, K. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int. Suppl. 1996, 63, S239-S243.
14. Stallforth, P.; Lepenies, B.; Adibekian, A.; Seeberger, P.H. Carbohydrates: A frontier in medicinal chemistry. J. Med. Chem. 2009, 52, 5561-5577.
15. Kren, V.; Martínková, L. Glycosides in medicine: "The role of glycosidic residue in biological activity". Curr. Med. Chem. 2001, 8, 303-1328.
16. Reynolds, D.D.; Evans, W.L. The synthesis of certain oligosaccharide acetates in the mannose series. J. Am. Chem. Soc. 1940, 62, 66-69.
17. Sixta, G.; Hofinger, A.; Kosma, P. Synthesis of spacer-containing chlamydial disaccharides as analogues of the a-Kdop-(2?8)-a-Kdop-(2?4)-a-Kdop trisaccharide epitope. Carbohydr. Res. 2007, 342, 576-585. (Pubitemid 46161396)
18. Klier, A.H.; Alves, R.J.; Auxiliadora, M.; Prado, F.; de Souza Filho J.D.; D'Accorso, N.B. Synthesis of new five membered nitrogen containing heterocycles bearing D-galactose side chains. Syn. Comm. 2000, 30, 4361-4374.
19. Lee, H.H.; Hodgson Philip, G.; Bernacki, R.J.; Korytnyk, W.; Sharma, M. Analogs of cell surface carbohydrates. Synthesis of D-galactose derivatives having an ethynyl, vinyl or epoxy residue at C-5. Carbohydr. Res. 1998, 176, 59-72.
20. Terreni, M.; Salvetti, R.; Linati, L.; Fernandez-Lafuente, R.; Fernandez-Lorento, G.; Bastida, A.; Guisan, J.M. Regioselective enzymatic hydrolysis of acetylated pyranoses and pyranosides using immobilised lipases. An easy chemoenzymatic synthesis of a- and -D-glucopyranose acetates bearing a free secondary c-4 hydroxyl group. Carbohydr. Res. 2002, 337, 1615-1622.
21. Horrobin, T.; Tran, C.H.; Crout, D. Esterase-catalysed regioselective 6-deacylation of hexopyranose per-acetates, acid-catalysed rearrangement to the 4-deprotected products and conversions of these into hexose 4- and 6-sulfates. J. Chem. Soc. Perkin Trans. 1 1998, 1069-1080. (Pubitemid 128758100)
22. Romero, D.L.; Morge, R.A.; Biles, C.; Berrios-Pena, N.; May, P.D.; Palmer, J.R.; Johnson, P.D.; Smith, H.W.; Busso, M.; Tan, C.K.; et al. Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 1994, 37, 999-1014. (Pubitemid 24140871)